Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 30, 2010 Cliff D'Arcy	Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline.
The Motley Fool April 30, 2010 Brian Orelli	Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter.
The Motley Fool October 14, 2010 Sean Williams	Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away.
The Motley Fool October 26, 2006 Brian Lawler	Market Rejects AstraZeneca's Remedy Investors pummel the pharmaceutical firm, despite its impressive results.
The Motley Fool February 5, 2007 Billy Fisher	A Fresh Outlook at AstraZeneca Strong performance makes management happy at the European drug giant. As long as the company is able to continue the strong revenue growth from its major contributors, shareholders will be able to enjoy a prosperous 2007.
The Motley Fool May 21, 2009 Robert Steyer	The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations?
The Motley Fool February 3, 2011 Owain Bennallack	Glaxo Sweetens a Bitter Pill The drugmaker reports a loss, but resumes share buybacks.
The Motley Fool July 27, 2006 Stephen D. Simpson	AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain.
The Motley Fool November 2, 2011 Prabhat Sakya	AstraZeneca vs. GlaxoSmithKline If you could only invest in one of these companies, which would it be?
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool January 27, 2005 Stephen D. Simpson	AstraZeneca Shines, for Now The British-Swedish drug company has a great quarter, but the future looks dimmer.
The Motley Fool February 1, 2008 Brian Lawler	AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs.
The Motley Fool December 1, 2008 Brian Orelli	It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies.
The Motley Fool February 12, 2004 Alyce Lomax	Depressing Year for Glaxo The pharmaceutical giant forecasts three lackluster quarters as copycats attack.
The Motley Fool December 29, 2006 Brian Lawler	Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.
BusinessWeek January 31, 2005 Kerry Capell	No Relief For AstraZeneca More bad news about potential blockbusters weakens Europe's third-largest drugmaker. Analysts say the only thing keeping Astra's shares from going into free fall is the mounting speculation that GSK might make a play for the troubled drugmaker.
The Motley Fool October 30, 2009 Brian Orelli	Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
BusinessWeek December 29, 2010 Kelley & Cortez	AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs.
The Motley Fool August 31, 2010 Brian Orelli	A Mostly Meaningless FDA Rejection The Food and Drug Administration sends AstraZeneca back to the drawing board for the second time when it rejected motavizumab, the drugmaker's newest treatment for respiratory syncytial virus.
The Motley Fool April 26, 2007 Brian Lawler	AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note.
The Motley Fool April 29, 2011 Brian Orelli	Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves.
The Motley Fool July 30, 2009 Brian Orelli	A Little Help From the Enemy Unfortunately, it won't last. AstraZeneca went over a small patent cliff, but its competitors were nice enough to throw it some climbing gear.
The Motley Fool March 5, 2010 Brian Orelli	How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot.
The Motley Fool May 31, 2007 Ryan Fuhrmann	Dueling Fools: Eli Lilly Bull Thanks to a couple of recent developments and a focus on research & development, the pharma giant is a worthy contender for health-care exposure in investors' portfolios.
The Motley Fool October 30, 2008 Brian Orelli	What's on Deck for AstraZeneca? The drugmaker increases EPS by cutting costs, but it's the next move that will count the most.
The Motley Fool October 30, 2007 Brian Lawler	ViroPharma Gets No Respect The drugmaker announces third-quarter results; sales of its only marketed drug, antibiotic treatment Vancocin, fell due to a higher level of wholesaler stocking. Investors, take note.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool April 28, 2005 Stephen D. Simpson	Standby Drugs Sustain AstraZeneca Sales are good now, but what will a weak pipeline mean to investors in a few years?
Chemistry World April 24, 2007 Victoria Gill	AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune.
The Motley Fool November 14, 2008 Brian Orelli	Gravy or Turkey From the FDA? Johnson & Johnson, Genzyme, and AstraZeneca should be made aware of their FDA fate over the next few weeks.
The Motley Fool August 20, 2007 Brian Lawler	Are These Perfect Pharma Acquisitions? Weighing recent drug-industry deals' odds of success: AstraZeneca and MedImmune... Shire and New River Pharmaceuticals... Gilead and Myogen...
The Motley Fool November 26, 2008 Brian Orelli	Teva and AstraZeneca's Drama Concludes Teva and AstraZeneca settle a lawsuit, but investors are still left in the dark.
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool November 1, 2004 Jeff Hwang	Is IVAX Ailing? Despite strong growth, competitive pricing pressures hurt results and the full-year forecast for the generic drug pharma.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
The Motley Fool October 27, 2005 Stephen D. Simpson	AstraZeneca Prepares for a Dry Spell A weak late-stage pipeline will make for challenging earnings growth in the coming years. Investors may want to hold out for a better price here.
The Motley Fool October 30, 2007 Brian Orelli	Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note.
The Motley Fool April 30, 2007 Brian Orelli	No Pain for Endo's Investors Endo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands. Investors, take note.
The Motley Fool March 29, 2010 Brian Orelli	5 Drugmakers Producing Cash for You Take greenbacks over earnings any day.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
BusinessWeek June 2, 2011 Kresge & Connolly	A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies.
The Motley Fool November 10, 2008 Brian Orelli	Drug Fuels an Idling Rocket Ship AstraZeneca needs another FDA approval to really take advantage of its cholesterol drug's success.
The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
The Motley Fool January 31, 2006 Stephen D. Simpson	Wyeth: Waiting on the Pipeline While Wyeth's growth today is modest, the late-stage pipeline could pay off. Investors, take note.
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.